In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 10, 2013, Pages 1518-1525

  Theile, Dirk ^a   Schmidt, Tobias T ^a   Haefeli, Walter E ^a   Weiss, Johanna ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

alcohol; drug metabolism; drug transporters; LS180; Pgp

Indexed keywords

ABC TRANSPORTER C2; ALCOHOL; CALCEIN; CARRIER PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2E1; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; ISOPENTYL ALCOHOL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; RIFAMPICIN; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCB11 GENE; ABCC2 GENE; ALCOHOL CONSUMPTION; ARTICLE; CELL STRAIN; CONTROLLED STUDY; CYP2C19 GENE; CYP2E1 GENE; CYP3A4 GENE; CYP3A5 GENE; DRINKING BEHAVIOR; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE STUDY; SLCO1B1 GENE; WESTERN BLOTTING;

ALCOHOL; DRUG METABOLISM; DRUG TRANSPORTERS; LS180; PGP;

ATP-BINDING CASSETTE TRANSPORTERS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; GENE EXPRESSION; HUMANS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PENTANOLS; TIME FACTORS;

EID: 84883739905     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12124     Document Type: Article

References (35)

1. Lieber CS,. Medical disorders of alcoholism. N Engl J Med 1995; 333: 1058-1065.
2. Greenberg DM, Lee JW,. Psychotic manifestations of alcoholism. Curr Psychiatry Rep 2001; 3: 314-318.
3. Hoensch H,. Ethanol as enzyme inducer and inhibitor. Pharmacol Ther 1987; 33: 121-128.
4. Le Couteur DG, et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005; 44: 187-200.
5. Verbeeck RK,. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-1161.
6. Lieber CS,. Metabolic effects of ethanol and its interaction with other drugs, hepatotoxic agents, vitamins, and carcinogens: a 1988 update. Semin Liver Dis 1988; 8: 47-68.
7. Klotz U, Ammon E,. Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 1998; 54: 7-12.
8. Neuvonen PJ, et al. Effect of long-term alcohol consumption on the half-life of tetracycline and doxycycline in man. Int J Clin Pharmacol Biopharm 1976; 14: 303-307.
9. Liangpunsakul S, et al. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology 2005; 41: 1144-1150.
10. Misra PS, et al. Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats. Am J Med 1971; 51: 346-351.
11. Sandor P, et al. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther 1981; 30: 390-397.
12. Couderc E, et al. Thiopentone pharmacokinetics in patients with chronic alcoholism. Br J Anaesth 1984; 56: 1393-1397.
13. Ciraulo DA, et al. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 1988; 43: 509-518.
14. Theile D, et al. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 (Suppl 1): E17-E22.
15. Shibata N, et al. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats. Biol Pharm Bull 2004; 27: 203-209.
16. Zinchuk V, et al. Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem Cell Biol 2007; 127: 503-512.
17. Greenshields RN,. Volatiles in home-brewed beers and wines. J Sci Food Agric 1974; 25: 1307-1312.
18. Kostrubsky VE, et al. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 1995; 322: 516-520.
19. Louis CA, et al. Synergistic increases in rat hepatic cytochrome P450s by ethanol and isopentanol. J Pharmacol Exp Ther 1994; 269: 838-845.
20. Gupta A, et al. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 2008; 36: 1172-1180.
21. Weiss J, et al. Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009; 109: 242-250.
22. König SK, et al. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 65: 2319-2328.
23. Harmsen S, et al. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab Dispos 2008; 36: 1166-1171.
24. McKee M, et al. The composition of surrogate alcohols consumed in Russia. Alcohol Clin Exp Res 2005; 29: 1884-1888.
25. Peters T, et al. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 291-299.
26. Weiss J, et al. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol 2011; 660: 298-304.
27. Yang H, et al. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010; 235: 32-39.
28. Weiss J, et al. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 2008; 579: 104-109.
29. Weiss J, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204.
30. Storch CH, et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-1581.
31. Feierman DE, et al. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res 2003; 27: 981-988.
32. Ho RH, Kim RB,. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260-277.
33. Lieber CS,. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol Clin Exp Res 1999; 23: 991-1007.
34. Koop DR, Tierney DJ,. Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 1990; 12: 429-435.
35. Girre C, et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47: 1503-1508